Filing Details

Accession Number:
0000903423-16-001320
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-10-26 17:49:47
Reporting Period:
2016-10-24
Filing Date:
2016-10-26
Accepted Time:
2016-10-26 17:49:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP Pharmaceutical Preparations (2834) X0
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1131399 Plc Glaxosmithkline 980 Great West Road
Brentford, Middlesex, X0 TW8 9GS
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2016-10-24 2,942,560 $0.00 2,942,560 No 4 C Indirect See explanation of responses
Common Shares Acquisiton 2016-10-24 211,567 $0.00 3,154,127 No 4 C Indirect See explanation of responses
Common Shares Acquisiton 2016-10-24 66,500 $14.00 3,220,627 No 4 P Indirect See explanation of responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See explanation of responses
No 4 C Indirect See explanation of responses
No 4 P Indirect See explanation of responses
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Series A-3 Preferred Shares Disposition 2016-10-24 2,942,560 $0.00 2,942,560 $0.00
Common Shares Series B Preferred Shares Disposition 2016-10-24 211,567 $0.00 211,567 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering.
  2. The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
  3. On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering
  4. Not applicable.